3 results match your criteria: "Massachusetts and an instructor in medicine at Harvard Medical School in Boston[Affiliation]"
A Facility-Wide Plan to Increase Access to Medication for Opioid Use Disorder in Primary Care and General Mental Health Settings.
Fed Pract
October 2021
is a Pr imary Care Physician; is an Addiction Psychiatrist and Substance Use Disorder Director, National TeleMental Health Center; is a Research Psychologist; is a Clinical Pharmacy Specialist in mental health (Clinical Resource Hub, Veterans Integrated Service Network 1); is a Clinical Psychologist; is a General Internist; is a Clinical Nurse Coordinator Outpatient Addiction; is an Addiction Psychiatrist; is a Primary Care Physician and National Co-Director for the Veterans Health Administration Primary Care Pain Initiative and Post Deployment Integrated Care Initiative; is an Addiction Psychiatrist and Director of Addiction Treatment programs; all at Veterans Affairs Connecticut Health Care System, in West Haven. is a Primary Care Physician at Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard Medical School in Boston, Massachusetts. is an Investigator and Staff Psychologist at Center for Care Delivery and Outcomes Research, Minneapolis Veterans Affairs Health Care System and an Assistant Professor of Medicine at the University of Minnesota School of Medicine. is a Physician, Chief of Addiction Medicine, and Core Faculty at Informatics, Decision-Enhancement, and Analytic Sciences Center, Veterans Affairs Salt Lake City Health Care System and a Professor of Medicine and Psychiatry and Director of the Program for Addiction Research, Clinical Care, Knowledge and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine in Salt Lake City. Marc Rosen is a Professor of Psychiatry; Andrea Burgo is an Assistant Clinical Professor of Medicine; Maria Garcia-Vassallo is an Assistant Professor of Psychiatry; William Becker is an Associate Professor of Medicine; Robert MacLean is an Assistant Professor of Psychiatry; Ellen Edens is an Associate Professor of Psychiatry; Juliette Spelman is an Assistant Professor of Medicine; Brent Moore is a Research Scientist; all at Yale School of Medicine in New Haven.
Background: The opioid epidemic in the United States has generated a pressing need to enhance access to medications for opioid use disorder (MOUD). This program description illustrates a quality-improvement effort to extend MOUD to primary care and general mental health clinics within the US Department of Veterans Affairs (VA) Connecticut Healthcare system (VACHS), and to examine barriers and facilitators to implementation of MOUD in target clinics.
Observations: As part of the national VA Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative to improve MOUD access, a VACHS team identified and resolved barriers to MOUD in target clinics.
Why Are Biosimilars Not Living up to Their Promise in the US?
AMA J Ethics
August 2019
A professor of medicine at Harvard Medical School in Boston, Massachusetts, and the director of the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital.
Biologics are among the most expensive prescription drugs in the United States, posing significant barriers to patient access to necessary treatments. An abbreviated approval pathway for biosimilars, near-identical versions of biologics made by different manufacturers, was created by Congress in 2010 to stimulate competition in hopes of driving down costs and expanding access. However, as of February 2019, only 17 biosimilars have been approved, with only 7 currently on the market.
View Article and Find Full Text PDFInfluence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease.
Gastroenterol Hepatol (N Y)
February 2019
Dr Vedamurthy is a hospitalist in the Division of General Medicine at Massachusetts General Hospital in Boston, Massachusetts and an instructor in medicine at Harvard Medical School in Boston, Massachusetts.
Inflammatory bowel disease (IBD), which mainly comprises Crohn's disease (CD) and ulcerative colitis (UC), is a term for chronic inflammatory diseases of the gut arising due to a dysregulated immune response to a dysbiotic gut microbiome on a background of genetic predisposition. However, genetics explains a small fraction of risk, and the external environment plays a large and important role in disease pathogenesis and natural history. Cigarette smoking, one of the earliest- and most-studied risk factors, increases the risk of CD onset and is associated with severe disease.
View Article and Find Full Text PDF